Fig. 1
From: A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model
Survival data for treated and untreated GL261 glioma-bearing mice. AG119 (n = 7), TMZ (n = 5), anti-c-Met antibody (n = 5), and anti-VEGF antibody (n = 5) treated GL261 glioma-bearing mice, compared to untreated controls (UT) (n = 5). When comparing AG119 (***p < 0.001; p = 0.0003) or TMZ (**p < 0.01; p = 0.0016) to UT, there was a significant increase in survival